Phase III Trial in Acute Promyelocytic Leukemia Patients
Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
The characteristic chromosomal abnormality associated with acute promyelocytic leukemia (APL) is t(15;17)(q22;q21). This translocation involves a breakpoint that includes the retinoic acid receptor and leads to production of the PML::RARA fusion protein.[1] Other more complex chromosomal rearrangements may also lead to a PML::RARA fusion and result in APL.
Sources: 1
Patients with a suspected diagnosis of APL can have their diagnosis confirmed by detection of the PML::RARA fusion protein through fluorescence in situ hybridization (FISH), reverse transcriptase–polymerase chain reaction (RT-PCR), or conventional cytogenetics. Quantitative RT-PCR allows identification of the three common transcript variants and is used for monitoring response on treatment and early detection of molecular relapse.[2] In addition, an immunofluorescence method using an anti-PML monoclonal antibody can rapidly establish the presence of the PML::RARA fusion protein based on the characteristic distribution pattern of PML that occurs in the presence of the fusion protein.[3-5]
Uncommon molecular variants of APL produce fusion proteins that join distinctive gene partners (e.g., PLZF, NPM, STAT5B, and NuMA) to RARA.[6,7] Recognition of these rare variants is important because they differ in their sensitivities to tretinoin and arsenic trioxide.[8]
PLZF::RARA fusion gene variant. The PLZF::RARA variant, characterized by t(11;17)(q23;q21), represents about 0.8% of APL, expresses surface CD56, and has very fine granules, compared with t(15;17) APL.[9-11] APL with the PLZF::RARA fusion gene has been associated with a poor prognosis and usually does not respond to tretinoin or arsenic trioxide.[8-11]
NPM::RARA or NuMA::RARA fusion gene variants. The rare APL variants with NPM::RARA (t(5;17)(q35;q21)) or NuMA::RARA (t(11;17)(q13;q21)) translocations may still be responsive to tretinoin.[8,12-15]
PML::RARA fusion gene variant. There are rare case reports of patients with PML::RARA fusion–negative APL. One such APL is the torque teno mini virus (TTMV) subtype.[16-18] This is a newly described entity in which the TTMV genome is integrated into intron 2 of the human RARA gene, resulting in a TTMV::RARA gene fusion. The clinical and morphological features of this APL subtype are similar to those of PML::RARA fusion–positive APL.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
FLT3 variants (either internal tandem duplication or tyrosine kinase domain variants) are observed in 40% to 50% of APL cases. The presence of FLT3 variants is correlated with higher white blood cell counts and the microgranular variant (M3v) subtype.[19-23] The FLT3 variant has previously been associated with an increased risk of induction death and, in some reports, an increased risk of treatment failure.[19-25] Given the extremely high cure rates for children with APL who were treated with tretinoin and arsenic trioxide, FLT3 variants are not associated with inferior outcomes.[26]
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
The prognostic significance of WBC count is used to define high-risk and low-risk patient populations and to assign induction treatment. High-risk patients are defined by a WBC count of 10 × 109/L or greater.[1,2] Patients with high-risk acute promyelocytic leukemia (APL) are given an anthracycline (idarubicin) along with induction therapy. Postinduction therapy is the same for both standard- and high-risk APL.[3]
APL in children is generally similar to APL in adults, although children have a higher incidence of hyperleukocytosis (defined as a WBC count higher than 10 × 109/L) and a higher incidence of the microgranular morphological subtype.[4-7] As in adults, children with WBC counts of less than 10 × 109/L at diagnosis have historically had better outcomes than patients with higher WBC counts.[5,6,8] Presenting WBC count is still used to determine induction therapy. However, with modern tretinoin- and arsenic trioxide–based therapy, patients with high-risk APL have similar excellent survival rates as patients with standard-risk APL.
In the Children's Oncology Group (COG) AAML0631 (NCT00866918) trial, which included treatment with chemotherapy, tretinoin, and arsenic trioxide, patients were stratified on the basis of WBC count to standard risk or high risk. Risk classification primarily defined early death risk rather than relapse risk (standard risk, 0 of 66 patients vs. high risk, 4 of 35 patients).[9] In the COG AAML1331 (NCT02339740) trial, patients were treated with tretinoin and arsenic trioxide along with aggressive supportive care measures. There was only 1 death (standard-risk APL) and 3 relapses (1 standard risk and 2 high risk) reported among 154 patients. Thus, no significant differences were seen between the risk groups.[3] In the COG AAML0631 (NCT00866918) and AAML1331 (NCT02339740) trials, relapse risk after remission induction was 4% and 2% overall, respectively.[3,9]
Sources: AAML0631 (NCT00866918) · 9 · AAML1331 (NCT02339740) · 3 · AAML0631 (NCT00866918) · AAML1331 (NCT02339740) · 3 · 9
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
For APL, MRD detection at the end of induction therapy lacks prognostic significance, likely related to the delayed clearance of differentiating leukemic cells destined to eventually die.[10,11] However, it is standard practice to document molecular remission after completion of two to four cycles of consolidation therapy.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.[2] This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[3] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 3 · NCI website
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Modern treatment programs for acute promyelocytic leukemia (APL) are based on the sensitivity of leukemia cells to the differentiation-inducing and apoptotic effects of tretinoin and arsenic trioxide. APL therapy first diverged from the therapy of other non-APL subtypes of acute myeloid leukemia (AML) with the addition of tretinoin to chemotherapy. With the incorporation of arsenic trioxide into modern treatment regimens, the use of traditional chemotherapy in adults and children is restricted to only the induction phase for high-risk patients.[1-3]
Treatment options for children with APL may include the following:
Arsenic trioxide and tretinoin, with or without chemotherapy.
Sources: Arsenic trioxide and tretinoin, with or without chemotherapy
Supportive care.
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Given the very high level of activity with the combination of arsenic trioxide and tretinoin for adults with APL [1,2] and data indicating that children with APL have a similar response to these agents,[3-7] the use of these two agents is the optimal therapeutic approach for this disease.
Induction therapy for patients with standard-risk APL includes repeated cycles of tretinoin and arsenic trioxide alone. Patients with high-risk APL receive treatment similar to that for patients with standard-risk disease, but they also receive short courses of chemotherapy during induction therapy.[3] Assessment of response to induction therapy in the first month of treatment using morphological and molecular criteria may provide misleading results because delayed persistence of differentiating leukemia cells can occur in patients who will ultimately achieve a complete remission (CR).[8,9] Alterations in planned treatment based on these early observations are not appropriate because it is rare for APL to be resistant to tretinoin plus arsenic trioxide.[3,10,11]
Almost all children with APL who were treated with tretinoin, arsenic trioxide, and modern supportive care achieved CR in the absence of coagulopathy-related mortality.[3,12-16]
Results from the completed cooperative group trial (Children's Oncology Group [COG] AAML1331 [NCT02339740]) verified the benefit of treatment with tretinoin and arsenic trioxide for children with newly diagnosed APL,[3] similar to results reported by other groups.[7] The dramatic efficacy of tretinoin against APL results from the ability of pharmacological doses of tretinoin to overcome the repression of signaling caused by the PML::RARA fusion protein at physiological tretinoin concentrations. Restoration of signaling leads to differentiation of APL cells and then to postmaturation apoptosis.[17] Most patients with APL achieve a CR when treated with tretinoin, although single-agent tretinoin is generally not curative.[18,19]
Arsenic trioxide, a proapoptotic and differentiation agent via binding to and the degradation of the PML::RARA fusion oncoprotein, is the most active agent in the treatment of APL. While initially used in patients with relapsed APL, it is now incorporated into the treatment of newly diagnosed patients. Data supporting the use of arsenic trioxide initially came from trials that included adult patients only, but its efficacy has now been seen in trials that included pediatric patients.
Based on the adult and pediatric experiences, consolidation therapy may include repeated cycles of tretinoin and arsenic trioxide without additional chemotherapy.[1-3,7] Studies using arsenic trioxide–based consolidation have demonstrated excellent survival rates without cytarabine consolidation.[1,3,7,20,21]
Based on data from adult trials and the COG AAML1331 (NCT02339740) trial, maintenance therapy is likely unnecessary for patients with APL who are treated with tretinoin and arsenic trioxide.[3] Because of the favorable outcomes with tretinoin and arsenic trioxide, hematopoietic stem cell transplant is not recommended in first CR.
Sources: AAML1331 (NCT02339740) · 3
Before this approach was discovered, chemotherapy was used in all or most phases of therapy including induction, consolidation, and maintenance for pediatric trials like AAML0631 (NCT00866918). The regimens that use chemotherapy are now primarily of historical interest. They can also be used as a reference in refractory cases because of the findings from randomized clinical trials that compared regimens with the combination of tretinoin and arsenic trioxide with or without chemotherapy.
Sources: AAML0631 (NCT00866918)
Evidence (arsenic trioxide and tretinoin, with or without chemotherapy):
In children and adolescents with newly diagnosed APL treated on the COG AAML0631 (NCT00866918) trial, two consolidation cycles of arsenic trioxide were incorporated into a chemotherapy regimen with lower cumulative anthracycline doses compared with historical controls.[22]
Sources: AAML0631 (NCT00866918) · 22
In children and adolescents with newly diagnosed APL treated on the COG AAML0631 (NCT00866918) trial, two consolidation cycles of arsenic trioxide were incorporated into a chemotherapy regimen with lower cumulative anthracycline doses compared with historical controls.[22]
The 3-year overall survival (OS) rate was 94%, and the event-free survival (EFS) rate was 91%.
Patients with standard-risk APL had an OS rate of 98% and an EFS rate of 95%.
Patients with high-risk APL had an OS rate of 86% and an EFS rate of 83%. This lower survival compared with standard-risk patients was primarily caused by early death events.
The relapse risk after arsenic trioxide consolidation was 4% and was similar for standard-risk and high-risk APL.
The concurrent use of arsenic trioxide and tretinoin in newly diagnosed patients with APL results in high rates of CR.[23-25] Early experience in children with newly diagnosed APL showed high rates of CR to arsenic trioxide, either as a single agent or given with tretinoin.[26][Level of evidence C1] Results of a meta-analysis of seven published studies in adult patients with APL suggested that using a combination of arsenic trioxide and tretinoin may be more effective than using arsenic trioxide alone to induce CR.[27]
Sources: 23 · 25 · 26 · Level of evidence C1 · 27
The concurrent use of arsenic trioxide and tretinoin in newly diagnosed patients with APL results in high rates of CR.[23-25] Early experience in children with newly diagnosed APL showed high rates of CR to arsenic trioxide, either as a single agent or given with tretinoin.[26][Level of evidence C1] Results of a meta-analysis of seven published studies in adult patients with APL suggested that using a combination of arsenic trioxide and tretinoin may be more effective than using arsenic trioxide alone to induce CR.[27]
In early trials in children, the impact of arsenic added to induction (either alone or with tretinoin) on EFS and OS had appeared promising.[26,28,29]
Arsenic trioxide was evaluated as a component of induction therapy with idarubicin and tretinoin in the APML4 clinical trial, which enrolled both children and adults (N = 124 evaluable patients).[20] Patients received two courses of consolidation therapy with arsenic trioxide and tretinoin (but no anthracycline) and maintenance therapy with tretinoin, mercaptopurine, and methotrexate.[30]
Arsenic trioxide was evaluated as a component of induction therapy with idarubicin and tretinoin in the APML4 clinical trial, which enrolled both children and adults (N = 124 evaluable patients).[20] Patients received two courses of consolidation therapy with arsenic trioxide and tretinoin (but no anthracycline) and maintenance therapy with tretinoin, mercaptopurine, and methotrexate.[30]
The 2-year freedom-from-relapse rate was 97.5%, the failure-free survival rate was 88.1%, and the OS rate was 93.2%.
These outcome results were superior to those reported for patients who did not receive arsenic trioxide in the predecessor clinical trial (APML3).
The historically controlled noninferiority COG AAML1331 (NCT02339740) trial was conducted between 2015 and 2019. The study included pediatric patients (age range, 1–21 years) with APL. The study examined whether the addition of arsenic trioxide to induction therapy, and continued through consolidation, could sustain the excellent outcomes seen in the AAML0631 (NCT00866918) trial. Additionally, chemotherapy was eliminated entirely, except when patients with high-risk APL were given short courses of idarubicin during induction therapy. Patients with standard risk APL, compared to past trials, had idarubicin eliminated from the induction cycle. Mitoxantrone, high-dose cytarabine, and idarubicin were eliminated from the consolidation cycles. Then, mercaptopurine and methotrexate were eliminated from the maintenance cycles. Intrathecal doses of cytarabine were also eliminated. The AAML1331 study included 154 patients, 98 of whom were classified as standard risk and 56 of whom were classified as high risk.[3] Standard-risk patients received tretinoin plus arsenic trioxide on days 1 to 28, with the possibility of continuing treatment up to day 70 to achieve a hematologic CR. High-risk patients received the same induction therapy schedule as standard-risk patients, with the addition of idarubicin on induction days 1, 3, 5, and 7. High-risk patients also received daily dexamethasone as a prophylactic treatment to prevent differentiation syndrome on days 1 to 14. All patients received the same consolidation therapy, which consisted of tretinoin on days 1 to 14 and days 29 to 42. Patients were also given arsenic trioxide 5 days each week for 4 consecutive weeks in every 8-week consolidation cycle for four cycles, although the fourth consolidation therapy cycle concluded on day 28. There was no maintenance therapy phase.[3]The AAML1331 and AAML0631 trials were compared and the following was reported:
Sources: AAML1331 (NCT02339740) · AAML0631 (NCT00866918) · 3 · 3
The historically controlled noninferiority COG AAML1331 (NCT02339740) trial was conducted between 2015 and 2019. The study included pediatric patients (age range, 1–21 years) with APL. The study examined whether the addition of arsenic trioxide to induction therapy, and continued through consolidation, could sustain the excellent outcomes seen in the AAML0631 (NCT00866918) trial. Additionally, chemotherapy was eliminated entirely, except when patients with high-risk APL were given short courses of idarubicin during induction therapy. Patients with standard risk APL, compared to past trials, had idarubicin eliminated from the induction cycle. Mitoxantrone, high-dose cytarabine, and idarubicin were eliminated from the consolidation cycles. Then, mercaptopurine and methotrexate were eliminated from the maintenance cycles. Intrathecal doses of cytarabine were also eliminated. The AAML1331 study included 154 patients, 98 of whom were classified as standard risk and 56 of whom were classified as high risk.[3] Standard-risk patients received tretinoin plus arsenic trioxide on days 1 to 28, with the possibility of continuing treatment up to day 70 to achieve a hematologic CR. High-risk patients received the same induction therapy schedule as standard-risk patients, with the addition of idarubicin on induction days 1, 3, 5, and 7. High-risk patients also received daily dexamethasone as a prophylactic treatment to prevent differentiation syndrome on days 1 to 14. All patients received the same consolidation therapy, which consisted of tretinoin on days 1 to 14 and days 29 to 42. Patients were also given arsenic trioxide 5 days each week for 4 consecutive weeks in every 8-week consolidation cycle for four cycles, although the fourth consolidation therapy cycle concluded on day 28. There was no maintenance therapy phase.[3]The AAML1331 and AAML0631 trials were compared and the following was reported:
The median duration of induction therapy for all patients (standard risk and high risk) was 47 days which included a 14-day rest period before starting consolidation therapy. All standard-risk and high-risk patients who completed their induction therapy achieved a hematologic CR or a CR with incomplete hematologic recovery before day 70.
During induction therapy, one standard-risk patient died of complications from coagulopathy, differentiation syndrome, and subsequent organ failure. No high-risk patients died of complications.
All patients who received quantitative polymerase chain reaction (PCR) testing after completing their second round of consolidation therapy were in molecular remission.
No patients experienced a relapse while on therapy. One standard-risk patient (1%) and two high-risk patients (4%) experienced relapses after therapy completion. These patients were successfully salvaged.
Standard-risk patients had equivalent 2-year EFS rates (98% vs. 97%) and OS rates (99% vs. 98.5%).
High-risk patients who enrolled in the AAML1331 trial had a significantly improved 2-year EFS rate (96.4% vs. 82.9%; P = .05) and OS rate (100% vs. 85.7%; P = .02).
In the AAML1331 trial, only a few patients with CNS symptoms or hemorrhage were examined and treated using triple intrathecal chemotherapy, whereas in the AAML0631 study, all standard-risk patients received three prophylactic doses of intrathecal chemotherapy, and all high-risk patients received four prophylactic doses of intrathecal chemotherapy.
The length of therapy was significantly shorter in the AAML1331 trial (9 months) than in the AAML0631 trial (>2 years).
Hospitalizations during consolidation therapy were significantly reduced in the AAML1331 trial, when compared with the AAML0631 trial (0 days vs. 13 days, respectively; P < .001).
In the AAML1331 trial, early death was significantly lower in high-risk patients (0 vs. 4 in AAML0631; P = .02), and not significantly different for standard-risk patients (1 vs. 0 in AAML0631; P = .16).
In summary, survival rates for children with APL exceeding 90% are achievable using treatment programs that prescribe the rapid initiation of tretinoin with appropriate supportive care measures and combine arsenic trioxide with tretinoin for induction and consolidation therapy.[3,7] Cytotoxic chemotherapy is required only for high-risk patients, and its use is restricted to induction therapy.[3] For patients in CR for more than 5 years, relapse is extremely rare.[31][Level of evidence B1]
Sources: 3 · 7 · 3 · 31 · Level of evidence B1
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
In addition to the previously mentioned universal presence of coagulopathy in patients newly diagnosed with APL (further described below), several other unique complications occur in patients with APL as a result of treatment. The clinician should be aware of these complications. These include two tretinoin-related conditions, pseudotumor cerebri and differentiation syndrome (also called retinoic acid syndrome), and an arsenic trioxide–related complication, QT interval prolongation.
Pseudotumor cerebri. Pseudotumor cerebri is typically manifested by headache, papilledema, sixth nerve palsy, visual field cuts, and normal intracranial imaging in the face of an elevated opening lumbar puncture pressure (not often obtained in APL patients). Pseudotumor cerebri is known to be associated with tretinoin, presumably by the same mechanism of vitamin A toxicity that leads to increased production of cerebrospinal fluid.The incidence of pseudotumor cerebri has been reported to be as low as 1.7% with very strict definitions of the complication and as high as 6% to 16% in pediatric trials.[3,12,22,32,33] Pseudotumor cerebri is thought to be more prevalent in children receiving tretinoin, leading to lower dosing in contemporary pediatric APL clinical trials.[3,33] Pseudotumor cerebri most typically occurs during induction at a median of 15 days (range, 1–35 days) after starting tretinoin, but is known to occur in other phases of therapy as well.[32] Pseudotumor cerebri incidence and severity may be exacerbated with the concurrent use of azoles via inhibition of cytochrome P450 metabolism of tretinoin.When a diagnosis of pseudotumor cerebri is suspected, tretinoin is withheld until symptoms abate and then is slowly escalated to full dose as tolerated.[32]
Differentiation syndrome. Differentiation syndrome (also known as retinoic acid syndrome or tretinoin syndrome) is a life-threatening syndrome thought to be an inflammatory response–mediated syndrome manifested by weight gain, fever, edema, pulmonary infiltrates, pleuro-pericardial effusions, hypotension, and, in the most severe cases, acute renal failure.[34] In the COG AAML0631 (NCT00866918) study, it was present in 20% of patients during induction. It was more prevalent in high-risk children (31%) than in low-risk children (13%), a risk factor also seen in adults with APL.[22,35] There is a bimodal peak with this syndrome seen in the first and third weeks of induction therapy. Since differentiation syndrome occurs more often in high-risk patients, dexamethasone is given with tretinoin and/or arsenic trioxide to prevent this complication.[34] Prophylaxis with dexamethasone and hydroxyurea (for cytoreduction) is also administered to standard-risk patients if their WBC count rises to greater than 10 × 109/L after the start of tretinoin or arsenic. If differentiation syndrome occurs, the patient's dexamethasone dose may be escalated with temporary withholding of tretinoin and arsenic trioxide and, similar to pseudotumor cerebri, restarted at a lower dose and escalated as tolerated. When this approach was used in the COG AAML1331 (NCT02339740) trial, 24.5% of standard-risk patients and 30.4% of high-risk patients presented with differentiation syndrome. Only one standard-risk patient died of differentiation syndrome and coagulopathy.[3]Patients with standard-risk APL who are treated during induction with tretinoin and arsenic trioxide alone, without other cytotoxic chemotherapy, have a risk of hyperleukocytosis (WBC count >10 × 109/L). The differentiating effect of tretinoin and arsenic trioxide can cause a rapid and significant rise in the WBC count after initiation of therapy. While hyperleukocytosis is a risk factor for developing differentiation syndrome, it may occur without developing the signs or symptoms of differentiation syndrome. In the COG AAML1331 trial, 32 of 98 patients with standard-risk APL developed hyperleukocytosis. This was managed with the initiation of hydroxyurea for cytoreduction and prophylaxis with dexamethasone to prevent differentiation syndrome. Patients with high-risk APL did not require hydroxyurea because they received idarubicin doses in early induction, which were effective for cytoreduction.[3]
Sources: 34 · AAML0631 (NCT00866918) · 22 · 35 · 34 · AAML1331 (NCT02339740) · 3 · 3
Coagulopathy. Along with differentiation syndrome, coagulopathy complications result in a higher risk of death during induction therapy (early death in APL). For more information about the diagnosis and management of coagulopathy, see the Clinical Presentation section.
Sources: Clinical Presentation
QT interval prolongation. Arsenic trioxide is associated with QT interval prolongation that can lead to life-threatening arrhythmias (e.g., torsades de pointes).[36] It is essential to monitor electrolytes closely in patients receiving arsenic trioxide and to maintain potassium and magnesium values at mid-reference ranges, as well as to be cognizant of other agents known to prolong the QT interval.[37]
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
The current induction and consolidation therapies result in molecular remission in most patients, as measured by reverse transcriptase (RT)-PCR for the PML::RARA fusion protein. Only 1% or less of patients show molecular evidence of disease at the end of consolidation therapy.[10,11] While two negative RT-PCR assays after completion of therapy are associated with long-term remission,[38] conversion from negative to positive RT-PCR is highly predictive of subsequent hematologic relapse.[39]
Patients with persistent or relapsing disease on the basis of PML::RARA fusion protein RT-PCR measurement may benefit from intervention with relapse therapies.[40,41] For more information, see the Treatment of Recurrent APL section.
Sources: 40 · 41 · Treatment of Recurrent APL
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Historically, 10% to 20% of patients with acute promyelocytic leukemia (APL) relapsed. However, current studies that incorporated arsenic trioxide therapy showed a cumulative incidence of relapse of less than 5%.[1-3]
In patients with APL who initially received chemotherapy-based treatments, the duration of first remission was prognostic. Patients who relapsed within 12 to 18 months of initial diagnosis had a worse outcome.[4-6]
An important issue in children who relapsed is the exposure to anthracyclines received in previous trials, which ranged from 400 mg/m2 to 750 mg/m2.[7] Thus, regimens containing anthracyclines were often not optimal for children with APL who relapsed.
Sources: 7
Treatment options for children with recurrent APL may include the following:
Arsenic trioxide with or without tretinoin.
Gemtuzumab ozogamicin.
Sources: Gemtuzumab ozogamicin
Hematopoietic stem cell transplant (HSCT).
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
For children with recurrent APL, the use of arsenic trioxide as a single agent or in regimens including tretinoin should be considered, depending on the therapy given during first remission. Arsenic trioxide is an active agent in adult patients with recurrent APL, with approximately 85% to 94% of patients achieving remission after treatment with this agent.[8-13] More limited data in children suggest that children with relapsed APL have a response to arsenic trioxide that is similar to that of adults.[8,10,13,14] Arsenic trioxide is well tolerated in children with relapsed APL, with a toxicity profile similar to that of adults.[8,13]
Arsenic trioxide is capable of inducing remissions in patients who relapse after having received arsenic trioxide with or without other agents during initial therapy.[13,15] However, APL cells may develop arsenic trioxide resistance when they acquire somatic variants in the PML domain of the PML::RARA fusion oncogene.[16]
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
In one trial, the use of gemtuzumab ozogamicin, an anti-CD33/calicheamicin antibody-drug conjugate, as a single agent resulted in a molecular remission rate of 91% (9 of 11 patients) after two doses and a molecular remission rate of 100% (13 of 13 patients) after three doses. These results demonstrate excellent activity of this agent in patients with relapsed APL.[19]
Sources: 19
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024. Captured 2026-09-09.
Retrospective pediatric studies have reported 5-year event-free survival (EFS) rates after either autologous or allogeneic transplant approaches to be similar, at approximately 70%.[20,21]
Evidence (autologous HSCT):
A study in adult patients treated with an autologous transplant demonstrated the following:[22]
Sources: 22
A study in adult patients treated with an autologous transplant demonstrated the following:[22]
There was an improved 7-year EFS rate (77% vs. 50%) when both the patient and the stem cell product had negative PML::RARA fusion transcripts by polymerase chain reaction (molecular remission) before transplant.
Another study demonstrated that among seven patients undergoing autologous HSCT and whose cells were minimal residual disease (MRD) positive, all relapsed in less than 9 months after transplant. However, only one of eight patients whose autologous donor cells were MRD negative relapsed.[23]
Sources: 23
An additional report demonstrated a difference in survival based on the treatment received during relapse.[24]
Sources: 24
An additional report demonstrated a difference in survival based on the treatment received during relapse.[24]
The 5-year EFS rate was 83.3% for patients who underwent autologous HSCT in second molecular remission.
The 5-year EFS rate was 34.5% for patients who received only maintenance therapy.
Another retrospective report found an improved survival for patients treated with HSCT after achieving a molecular remission.[13]
Sources: 13
Another retrospective report found an improved survival for patients treated with HSCT after achieving a molecular remission.[13]
Ninety-four percent of pediatric and adult patients (64 of 67) with relapsed APL, after primarily receiving single-agent arsenic trioxide, achieved a molecular remission after treatment with arsenic-containing reinduction regimens.
For patients who received postremission consolidation with HSCT (n = 35), the 5-year overall survival (OS) rate was 90.3% (± 5.3%), and the EFS rate was 87.1% (± 6.0%). These outcomes were significantly superior to the outcomes of patients who received an arsenic-containing maintenance regimen, which resulted in a 5-year OS rate of 58.6% (± 10.4%) and an EFS rate of 47.7% (± 10.3%).
Such data support the use of autologous transplant in patients who are MRD negative in second complete remission and have MRD-negative stem cell collections.
Because of the rarity of APL in children and the favorable outcome for this disease, clinical trials in relapsed APL to compare treatment approaches are likely not feasible. However, an international expert panel provided recommendations for the treatment of relapsed APL on the basis of the reported pediatric and adult experiences.[25]
Sources: 25
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed childhood acute promyelocytic leukemia (APL) may include the following:
Sources: diagnosed · acute promyelocytic leukemia
Tretinoin with arsenic trioxide.
Sources: Tretinoin · arsenic trioxide
Tretinoin plus chemotherapy with or without arsenic trioxide.
Sources: chemotherapy
Supportive care.
Sources: Supportive care
Treatment of childhood APL during the remission phase (consolidation/intensification therapy) may include the following:
Sources: remission · consolidation · intensification therapy
Tretinoin with arsenic trioxide.
Tretinoin plus chemotherapy with or without arsenic trioxide.
Treatment of childhood APL during the remission phase (maintenance therapy) may include the following:
Sources: maintenance therapy
Tretinoin with combination chemotherapy.
Sources: combination chemotherapy
Treatment of recurrent childhood APL may include the following:
Sources: recurrent
Arsenic trioxide therapy with or without tretinoin.
Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).
Sources: Targeted therapy · monoclonal antibody · gemtuzumab ozogamicin
Stem cell transplant using blood stem cells from the patient or a donor.
Sources: Stem cell transplant · blood stem cells · donor
Leukemia
ClinicalTrials.gov recordChildhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
ClinicalTrials.gov recordAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
ClinicalTrials.gov recordAcute Promyelocytic Leukemia in children and adolescents
Treatment of Recurrent APL
TRISENOX is an arsenical indicated: In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or...
DailyMed label